Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Sage Therapeutics (SAGE) PT Raised to $220 at Canaccord, Says SAGE-217 is 'Potential Game Changer'
-
Sage Therapeutics (SAGE) PT Raised to $220 at Canaccord, 'Paving an Expedited Path Forward for SAGE-217'
-
Sage Therapeutics (SAGE) PT Raised to $191 at Canaccord Genuity
-
Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord Genuity
-
UPDATE: Sage Therapeutics (SAGE) PT Lowered to $81 at Canaccord Genuity
-
SAGE Therapeutics (SAGE): SAGE extends blinding through secondary endpoints for Phase 3 - Canaccord Genuity
-
SAGE Therapeutics (SAGE) Prices 4.4M Common Stock Offering at $39.75/Share
-
Sage Therapeutics Announces Pricing of Public Offering of Common Stock
-
Sage Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference
-
SAGE Therapeutics (SAGE) Prices 3.16M Shares at $47.50/Share
-
Sage Therapeutics Announces Pricing of Public Offering of Common Stock
-
SAGE Therapeutics (SAGE) Announces $150M Common Stock Offering
-
Sage Therapeutics Announces Proposed Public Offering of Common Stock
-
SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
-
Canaccord Genuity Raised the Price Target to $85 on SAGE Therapeutics (SAGE) as they Prepare to Enter Phase 3 STATUS Trial
-
SAGE Therapeutics Announces Participation in February Conferences
-
UPDATE: Canaccord Genuity Starts Sage Therapeutics (SAGE) at Buy
-
Notable Analyst Rating Changes 08/12: (ANF) (ICUI) (DF) Upgraded; (AMCC) (WHX) (TCK) Downgraded
-
SAGE Therapeutics (SAGE) IPO Surges 50% Higher
